治疗非酒精性脂肪性肝病的相关药物及机制
Drugs and Mechanisms Related to the Treatment of Nonalcoholic Fatty Liver Disease
DOI: 10.12677/ACM.2021.1111773, PDF,    科研立项经费支持
作者: 牟 钊, 陈雨琳, 蒲 柯, 杨国栋*：川北医学院附属医院消化内科，四川 南充
关键词: 非酒精性肝病；发生机制；治疗；Nonalcoholic Fatty Liver Disease； Mechanism； Treatment
摘要: 非酒精性脂肪性肝病(nonalcoholic fatty liver disease, NAFLD)发病率逐渐升高，该病不断进展为肝纤维化和肝癌，已成为全球亟待解决的问题，目前还没有治疗NALFD的特效药。该综述总结了与NAFLD相关药物及其作用机制，为开展新的研究、寻求NALFD治疗方案提供新的思路及依据。
Abstract: The incidence of nonalcoholic fatty liver disease (NAFLD) is gradually increasing, and the disease continues to progress to liver fibrosis and liver cancer, which has become an urgent problem worldwide, and there is no specific drug for the treatment of NALFD. This review summarizes the drugs related to NAFLD and their mechanisms of action, providing new ideas and basis for carrying out new studies and seeking NALFD treatment options.
文章引用：牟钊, 陈雨琳, 蒲柯, 杨国栋. 治疗非酒精性脂肪性肝病的相关药物及机制[J]. 临床医学进展, 2021, 11(11): 5237-5244. https://doi.org/10.12677/ACM.2021.1111773

参考文献

[1] Wong, V.W., Chan, W.K., Chitturi, S., Chawla, Y., Dan, Y.Y., Duseja, A., et al. (2018) Asia-Pacific Working Party on Non-Alcoholic Fatty Liver Disease Guidelines 2017-Part 1: Definition, Risk Factors and Assessment. Journal of Gastroenterology and Hepatology, 33, 70-85. [Google Scholar] [CrossRef] [PubMed]
[2] Tilg, H., Moschen, A.R. and Roden, M. (2017) NAFLD and Diabetes Mellitus. Nature Reviews Gastroenterology & Hepatology, 14, 32-42. [Google Scholar] [CrossRef] [PubMed]
[3] Armstrong, M.J., Adams, L.A., Canbay, A. and Syn, W.-K. (2014) Extrahepatic Complications of Nonalcoholic Fatty Liver Disease. Hepatology, 59, 1174-1197. [Google Scholar] [CrossRef] [PubMed]
[4] Foretz, M., Guigas, B., Bertrand, L., Pollak, M. and Viollet, B. (2014) Metformin: From Mechanisms of Action to Therapies. Cell Metabolism, 20, 953-966. [Google Scholar] [CrossRef] [PubMed]
[5] Flory, J. and Lipska, K. (2019) Metformin in 2019. JAMA, 321, 1926-1927. [Google Scholar] [CrossRef] [PubMed]
[6] Viollet, B., Guigas, B., Sanz, G.N., Leclerc, J., Foretz, M. and Andreelli, F. (2012) Cellular and Molecular Mechanisms of Metformin: An Overview. Clinical Science, 122, 253-270. [Google Scholar] [CrossRef] 
[7] Evans, T.D., Zhang, X., Jeong, S.J., He, A., Song, E., Bhattacharya, S., et al. (2019) TFEB Drives PGC-1α Expression in Adipocytes to Protect against Diet-Induced Metabolic Dysfunction. Science Signaling, 12, Article No. eaau2281. [Google Scholar] [CrossRef] [PubMed]
[8] Zhang, D., Ma, Y., Liu, J., Deng, Y., Zhou, B., Wen, Y., et al. (2021) Metformin Alleviates Hepatic Steatosis and Insulin Resistance in a Mouse Model of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease by Promoting Transcription Factor EB-Dependent Autophagy. Frontiers in Pharmacology, 12, Article No. 689111. [Google Scholar] [CrossRef] [PubMed]
[9] 王玉莹, 刘蕴玲. 二甲双胍治疗非酒精性脂肪性肝病的研究进展[J]. 临床内科杂志, 2021, 38(5): 355-357.
[10] Soccio, R.E., Chen, E.R. and Lazar, M.A. (2014) Thiazolidinediones and the Promise of Insulin Sensitization in Type 2 Diabetes. Cell Metabolism, 20, 573-591. [Google Scholar] [CrossRef] [PubMed]
[11] Belfort, R., Harrison, S.A., Brown, K., Darland, C., Finch, J., Hardies, J., et al. (2006) A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis. New England Journal of Medicine, 355, 2297-2307. [Google Scholar] [CrossRef] 
[12] Aithal, G.P., Thomas, J.A., Kaye, P.V., Lawson, A., Ryder, S.D., Spendlove, I., et al. (2008) Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects with Nonalcoholic Steatohepatitis. Gastroenterology, 135, 1176-1184. [Google Scholar] [CrossRef] [PubMed]
[13] Lewis, J.D., Habel, L.A., Quesenberry, C.P., Strom, B.L., Peng, T., Hedderson, M.M., et al. (2015) Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons with Diabetes. JAMA, 314, 265-277. [Google Scholar] [CrossRef] [PubMed]
[14] Yau, H., Rivera, K., Lomonaco, R. and Cusi, K. (2013) The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus. Current Diabetes Reports, 13, 329-341. [Google Scholar] [CrossRef] [PubMed]
[15] Andersen, A., Lund, A., Knop, F.K. and Vilsbøll, T. (2018) Glucagon-Like Peptide 1 in Health and Disease. Nature Reviews Endocrinology, 14, 390-403. [Google Scholar] [CrossRef] [PubMed]
[16] Armstrong, M.J., Hull, D., Guo, K., Barton, D., Hazlehurst, J.M., Gathercole, L.L., et al. (2016) Glucagon-Like Peptide 1 Decreases Lipotoxicity in Non-Alcoholic Steatohepatitis. Journal of Hepatology, 64, 399-408. [Google Scholar] [CrossRef] [PubMed]
[17] Seghieri, M., Rebelos, E., Gastaldelli, A., Astiarraga, B.D., Casolaro, A., Barsotti, E., et al. (2013) Direct Effect of GLP-1 Infusion on Endogenous Glucose Production in Humans. Diabetologia, 56, 156-161. [Google Scholar] [CrossRef] [PubMed]
[18] Xiao, C., Dash, S., Morgantini, C., Adeli, K. and Lewis, G.F. (2015) Gut Peptides Are Novel Regulators of Intestinal Lipoprotein Secretion: Experimental and Pharmacological Manipulation of Lipoprotein Metabolism. Diabetes, 64, 2310-2318. [Google Scholar] [CrossRef] [PubMed]
[19] Armstrong, M.J., Gaunt, P., Aithal, G.P., et al. (2016) Liraglutide Safety and Efficacy in Patients with Non-Alcoholic Steatohepatitis (LEAN): A Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Study. Lancet, 387, 679-690. [Google Scholar] [CrossRef] 
[20] Yakaryilmaz, F., Guliter, S., Savas, B., Erdem, O., Ersoy, R., Erden, E., et al. (2007) Effects of Vitamin E Treatment on Peroxisome Proliferator-Activated Receptor-Alpha Expression and Insulin Resistance in Patients with Non-Alcoholic Steatohepatitis: Results of a Pilot Study. Internal Medicine Journal, 37, 229-235. [Google Scholar] [CrossRef] [PubMed]
[21] Abner, E.L., Schmitt, F.A., Mendiondo, M.S., Marcum, J.L. and Kryscio, R.J. (2011) Vitamin E and All-Cause Mortality: A Meta-Analysis. Current Aging Science, 4, 158-170. [Google Scholar] [CrossRef] [PubMed]
[22] Klein, E.A., Thompson, I.J., Tangen, C.M., Crowley, J.J., Lucia, M.S., Goodman, P.J., et al. (2011) Vitamin E and the Risk of Prostate Cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA, 306, 1549-1556. [Google Scholar] [CrossRef] [PubMed]
[23] Dufour, J.F., Oneta, C.M., Gonvers, J.J., Bihl, F., Cerny, A., Cereda, J.M., et al. (2006) Randomized Placebo-Controlled Trial of Ursodeoxycholic Acid with Vitamin E in Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 4, 1537-1543. [Google Scholar] [CrossRef] [PubMed]
[24] Leuschner, U.F., Lindenthal, B., Herrmann, G., Arnold, J.C., Rössle, M., Cordes, H.-J., et al. (2010) High-Dose Ursodeoxycholic Acid Therapy for Nonalcoholic Steatohepatitis: A Double-Blind, Randomized, Placebo-Controlled Trial. Hepatology, 52, 472-479. [Google Scholar] [CrossRef] [PubMed]
[25] Lindor, K.D., Kowdley, K.V., Heathcote, E.J., Harrison, M.E., Jorgensen, R., Angulo, P., et al. (2004) Ursodeoxycholic Acid for Treatment of Nonalcoholic Steatohepatitis: Results of a Randomized Trial. Hepatology, 39, 770-778. [Google Scholar] [CrossRef] [PubMed]
[26] Masterton, G.S., Plevris, J.N. and Hayes, P.C. (2010) Review Article: Omega-3 Fatty Acids—A Promising Novel Therapy for Non-Alcoholic Fatty Liver Disease. Alimentary Pharmacology & Therapeutics, 31, 679-692. [Google Scholar] [CrossRef] 
[27] Sanyal, A.J., Abdelmalek, M.F., Suzuki, A., Cummings, O.W. and Chojkier, M. (2014) No Significant Effects of Ethyl-Eicosapentanoic Acid on Histologic Features of Nonalcoholic Steatohepatitis in a Phase 2 Trial. Gastroenterology, 147, 377-384.E1. [Google Scholar] [CrossRef] [PubMed]
[28] Balabanov, S., Braig, M., Brummendorf, T.H. (2014) Current Aspects in Resistance against Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia. Drug Discovery Today: Technologies, 11, 89-99. [Google Scholar] [CrossRef] [PubMed]
[29] Wolf, A.M., Wolf, D., Rumpold, H., Ludwiczek, S., Enrich, B., Gastl, G., et al. (2005) The Kinase Inhibitor Imatinib Mesylate Inhibits TNF-α Production in Vitro and Prevents TNF-Dependent Acute Hepatic Inflammation. Proceedings of the National Academy of Sciences of the United States of America, 102, 13622-13627. [Google Scholar] [CrossRef] [PubMed]
[30] Al Asfoor, S., Rohm, T.V., Bosch, A., Dervos, T., Calabrese, D., Matter, M.S., et al. (2018) Imatinib Reduces Non-Alcoholic Fatty Liver Disease in Obese Mice by Targeting Inflammatory and Lipogenic Pathways in Macrophages and Liver. Scientific Reports, 8, Article No. 15331. [Google Scholar] [CrossRef] [PubMed]
[31] Chawla, A. (2010) Control of Macrophage Activation and Function by PPARs. Circulation Research, 106, 1559-1569. [Google Scholar] [CrossRef] 
[32] Souza-Mello, V. (2015) Peroxisome Proliferator-Activated Receptors as Targets to Treat Non-Alcoholic Fatty Liver Disease. World Journal of Hepatology, 7, 1012-1019. [Google Scholar] [CrossRef] [PubMed]
[33] Chan, S.M., Sun, R.Q., Zeng, X.Y., Choong, Z.H., Wang, H., Watt, M.J., et al. (2013) Activation of PPARalpha Ameliorates Hepatic Insulin Resistance and Steatosis in High Fructose-Fed Mice Despite Increased Endoplasmic Reticulum Stress. Diabetes, 62, 2095-2105. [Google Scholar] [CrossRef] [PubMed]
[34] Magliano, D.C., Bargut, T.C., de Carvalho, S.N., Aguila, M.B., Mandarim-de-Lacerda, C.A., Souza-Mello, V., et al. (2013) Peroxisome Proliferator-Activated Receptors-Alpha and Gamma Are Targets to Treat Offspring from Maternal Diet-Induced Obesity in Mice. PLoS ONE, 8, Article ID: e64258. [Google Scholar] [CrossRef] [PubMed]
[35] Federico, A., Dallio, M., Caprio, G.G., Ormando, V.M. and Loguercio, C. (2017) Gut Microbiota and the Liver. Minerva Gastroenterologica e Dietologica, 63, 385-398. [Google Scholar] [CrossRef] 
[36] Kobyliak, N., Conte, C., Cammarota, G., Haley, A.P., Styriak, I., Gaspar, L., et al. (2016) Probiotics in Prevention and Treatment of Obesity: A Critical View. Nutrition & Metabolism, 13, Article No. 14. [Google Scholar] [CrossRef] [PubMed]
[37] Kobyliak, N., Abenavoli, L., Falalyeyeva, T., Mykhalchyshyn, G., Boccuto, L., Kononenko, L., et al. (2018) Beneficial Effects of Probiotic Combination with Omega-3 Fatty Acids in NAFLD: A Randomized Clinical Study. Minerva Medica, 109, 418-428. [Google Scholar] [CrossRef] 
[38] 王薇, 史林平, 石蕾, 等. 肠道益生菌辅助治疗非酒精性脂肪性肝病的临床研究[J]. 中华内科杂志, 2018, 57(2): 101-106.
[39] Brooks, S.R., Brooks, J.S., Lee, W.H., Lee, M.G. and Kim, S.G. (2009) Therapeutic Potential of Dithiolethiones for Hepatic Diseases. Pharmacology & Therapeutics, 124, 31-43. [Google Scholar] [CrossRef] [PubMed]
[40] Kim, W., Kim, B.G., Lee, J.S., Lee, C.K., Yeon, J.E., Chang, M.S., et al. (2017) Randomised Clinical Trial: The Efficacy and Safety of Oltipraz, a Liver X Receptor Alpha-Inhibitory Dithiolethione in Patients with Non-Alcoholic Fatty Liver Disease. Alimentary Pharmacology & Therapeuticsr, 45, 1073-1083. [Google Scholar] [CrossRef] [PubMed]
[41] Konikoff, F.M. and Gilat, T. (2005) Effects of Fatty Acid Bile Acid Conjugates (FABACs) on Biliary Lithogenesis: Potential Consequences for Non-Surgical Treatment of Gallstones. Current Drug Targets—Immune, Endocrine & Metabolic Disorders, 5, 171-175. [Google Scholar] [CrossRef] [PubMed]
[42] Dobrzyn, A. and Ntambi, J.M. (2005) Stearoyl-CoA Desaturase as a New Drug Target for Obesity Treatment. Obesity Reviews, 6, 169-174. [Google Scholar] [CrossRef] 
[43] Safadi, R., Konikoff, F.M., Mahamid, M., Zelber-Sagi, S., Halpern, M., Gilat, T., et al. (2014) The Fatty Acid-Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients with Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 12, 2085-2091.E1. [Google Scholar] [CrossRef] [PubMed]
[44] Lancaster, L., Morrison, L., Auais, A., Ding, B., Iqbal, A., Polman, B., et al. (2017) Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis: Experience from 92 Sites in an Open-Label US Expanded Access Program. Pulmonary Therapy, 3, 317-325. [Google Scholar] [CrossRef] [PubMed]
[45] Garcia, L., Hernandez, I., Sandoval, A., Salazar, A., Garcia, J., Vera, J., et al. (2002) Pirfenidone Effectively Reverses Experimental Liver Fibrosis. Journal of Hepatology, 37, 797-805. [Google Scholar] [CrossRef] 
[46] Tsuchiya, H., Kaibori, M., Yanagida, H., Yokoigawa, N., Kwon, A.H., Okumura, T., et al. (2004) Pirfenidone Prevents Endotoxin-Induced Liver Injury after Partial Hepatectomy in Rats. Journal of Hepatology, 40, 94-101. [Google Scholar] [CrossRef] [PubMed]
[47] Wang, F., Wen, T., Chen, X.Y. and Wu, H. (2008) Protective Effects of Pirfenidone on D-Galactosamine and Lipopolysaccharide-Induced Acute Hepatotoxicity in Rats. Inflammation Research, 57, 183-188. [Google Scholar] [CrossRef] [PubMed]
[48] Chen, G., Ni, Y., Nagata, N., Xu, L., Zhuge, F., Nagashimada, M., et al. (2019) Pirfenidone Prevents and Reverses Hepatic Insulin Resistance and Steatohepatitis by Polarizing M2 Macrophages. Laboratory Investigation, 99, 1335-1348. [Google Scholar] [CrossRef] [PubMed]
[49] Volkmann, X., Fischer, U., Bahr, M.J., Ott, M., Lehner, F., MacFarlane, M., et al. (2007) Increased Hepatotoxicity of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Diseased Human Liver. Hepatology, 46, 1498-1508. [Google Scholar] [CrossRef] [PubMed]
[50] Farrell, G.C., Larter, C.Z., Hou, J.Y., Zhang, R.H., Yeh, M.M., Williams, J., et al. (2009) Apoptosis in Experimental NASH Is Associated with p53 Activation and TRAIL Receptor Expression. Journal of Gastroenterology and Hepatology, 24, 443-452. [Google Scholar] [CrossRef] [PubMed]
[51] Barreyro, F.J., Holod, S., Finocchietto, P.V., Camino, A.M., Aquino, J.B., Avagnina, A., et al. (2015) The Pan-Caspase Inhibitor Emricasan (IDN-6556) Decreases Liver Injury and Fibrosis in a Murine Model of Non-Alcoholic Steatohepatitis. Liver International, 35, 953-966. [Google Scholar] [CrossRef] [PubMed]
[52] Staels, B., Handelsman, Y. and Fonseca, V. (2010) Bile Acid Sequestrants for Lipid and Glucose Control. Current Diabetes Reports, 10, 70-77. [Google Scholar] [CrossRef] [PubMed]
[53] Braunlin, W., Zhorov, E., Guo, A., Apruzzese, W., Xu, Q., Hook, P., et al. (2002) Bile Acid Binding to Sevelamer HCl. Kidney International, 62, 611-619. [Google Scholar] [CrossRef] [PubMed]
[54] Harach, T., Pols, T.W., Nomura, M., Maida, A., Watanabe, M., Auwerx, J., et al. (2012) TGR5 Potentiates GLP-1 Secretion in Response to Anionic Exchange Resins. Scientific Reports, 2, Article No. 430. [Google Scholar] [CrossRef] [PubMed]
[55] Kobayashi, M., Ikegami, H., Fujisawa, T., Nojima, K., Kawabata, Y., Noso, S., et al. (2007) Prevention and Treatment of Obesity, Insulin Resistance, and Diabetes by Bile Acid-Binding Resin. Diabetes, 56, 239-247. [Google Scholar] [CrossRef] [PubMed]

为你推荐